Skip to main content
Curtis Hanson, MD, Pathology, Rochester, MN

CurtisAHansonMD

Pathology • Rochester, MN

Hematopathology, Anatomic Pathology, Clinical Pathology

Hematopathology at Mayo Clinic

Join to view full profile

Dr. Hanson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Hanson's full profile

Already have an account?

  • Office

    200 1st St SW
    Rochester, MN 55905
    Phone+1 507-284-2511

Education & Training

  • University of Minnesota
    University of MinnesotaResidency, Pathology-Anatomic and Clinical, 1983 - 1987
  • M Health Fairview
    M Health FairviewInternship, Transitional Year, 1982 - 1983
  • University of Iowa Roy J. and Lucille A. Carver College of Medicine
    University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 1982

Certifications & Licensure

  • MN State Medical License
    MN State Medical License 1993 - 2025
  • NJ State Medical License
    NJ State Medical License 2004 - 2019
  • MI State Medical License
    MI State Medical License 1987 - 1994
  • American Board of Pathology Anatomic Pathology & Clinical Pathology
  • American Board of Pathology Hematology

Publications & Presentations

PubMed

Abstracts/Posters

  • Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E19...
    Curtis A. Hanson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis
    Curtis A. Hanson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ...
    Curtis A. Hanson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • A Prospective Evaluation of Vitamin B1 (thiamine) Level in Myeloproliferative Neoplasms: Clinical Correlations and Impact of JAK2 Inhibitor Therapy 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Determinants of Long-Term Outcome in Type 1/like Calreticulin-Mutated Myelofibrosis 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • The Germline JAK2 GGCC (46/1) Haplotype and Survival Among 414 Molecularly-Annotated Patients with Primary Myelofibrosis 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Centralized Cardiac Monitoring Center Developed by Cleveland Clinic
    Centralized Cardiac Monitoring Center Developed by Cleveland ClinicOctober 25th, 2017
  • Primary Care Docs Spending About Half Their Work Days Interacting with EHRs
    Primary Care Docs Spending About Half Their Work Days Interacting with EHRsOctober 13th, 2017
  • Lab Rules Firing at the Time of Test Order; Possible on the LIS?
    Lab Rules Firing at the Time of Test Order; Possible on the LIS?October 9th, 2017
  • Join now to see all

Dr. Curtis Hanson, Dr. Curtis Hanson, MD, Dr. C Hanson, Dr. Curtis A Hanson